Rafferty Asset Management’s Acceleron Pharma XLRN Stock Holding History

Rafferty Asset Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-23,532	Closed	-$4.05M	–	1352
2021 Q3	$4.05M	Buy	23,532 +3,985	+20%	+$521K	0.03%	360
2021 Q2	$2.45M	Sell	19,547 -4,676	-19%	-$590K	0.02%	616
2021 Q1	$3.29M	Buy	24,223 +16,722	+223%	+$2.16M	0.02%	429
2020 Q4	$960K	Sell	7,501 -14,448	-66%	-$1.69M	0.01%	509
2020 Q3	$2.47M	Buy	21,949 +11,942	+119%	+$1.19M	0.03%	358
2020 Q2	$953K	Buy	10,007 +6,748	+207%	+$650K	0.01%	562
2020 Q1	$293K	Sell	3,259 -24,427	-88%	-$1.9M	0.01%	443
2019 Q4	$1.47M	Sell	27,686 -22,497	-45%	-$1.03M	0.02%	458
2019 Q3	$1.98M	Sell	50,183 -3,231	-6%	-$140K	0.03%	386
2019 Q2	$2.19M	Sell	53,414 -19,382	-27%	-$802K	0.04%	389
2019 Q1	$3.39M	Buy	+72,796	New	+$3.2M	0.05%	193

Rafferty Asset Management's XLRN Position: Q4 2021 in Review

Rafferty Asset Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 23,532 shares — an estimated $4.05M sold.

Rafferty Asset Management first reported a position in XLRN in Q1 2019 and held it in 11 quarters. The position peaked at $4.05M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Rafferty Asset Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Rafferty Asset Management sold 23,532 Acceleron Pharma shares in Q4 2021, an estimated $4.05M.
Rafferty Asset Management first reported a position in Acceleron Pharma in Q1 2019 and held it in 11 quarters.
Rafferty Asset Management's Acceleron Pharma position peaked at $4.05M in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Rafferty Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.